Investor Area

Home / Investor Area / Nomura Quick Note: “Vitiligo and EPP opportunities progress”

Nomura Quick Note: “Vitiligo and EPP opportunities progress”

CUV has released: 1) clinically impressive interim Phase II Vitiligo trial results; and 2) US FDA agreement to be allowed to conduct a Phase III study in erythropoietic protoporphyria (EPP).